Synthetic Tables


Drug

CV complication

Percentage

Dosage

Alemtuzumab

Hypotension, heart failure

Rare
 
Arsenic trioxide

QT prolongation

26–93 %
 
Axitinib

Hypertension

4–16 %
 
Bevacizumab

Thromboembolic arterial complications

12 %
 
CHF

1.7–3 %

Hypertension

4–35 %

Ischemia

0.6–1.5 %

Bortezomib

CHF

2–5 %
 
Busulfan

Endomyocardial fibrosis, pericardial effusions
 
>600 mg

Capecitabine

Ischemia less frequent than 5-FU

3–9 %
 
Cetuximab

Hypotension (during reaction: bronchospasm, stridor, urticaria)
  
Cyclophosphamide [1–3]

Pericardial effusions, heart failure, and myopericarditis

7–28 %

>100–120 mg/kg

Patients undergoing autologous or allogeneic HSCT

5–10 %
 
Cisplatin

Heart failure

8 %

>400 mg/m2

Thromboembolic complications (venous thromboembolism)

18 %
 
Cytarabine ARA-C

Pericarditis, heart failure in association with cyclophosphamide
  
Clofarabine

CHF transient

27 %
 
Dasatinib

CHF

2–4 %
 
Pericarditis

Rare

QT prolongation

<1–3 %

Docetaxel

CHF

2.3–8 %
 
Ischemia

1.7 %

Doxorubicin

Heart failure

3–26 %

400 mg/mq

Heart failure

18–48 %

550 mg/mq

Dovitinib

No data
  
Epirubicin [4]

Heart failure

0.9–3.3 %

>800 mg/m2

Clinically overt cardiotoxicity

6 %

Subclinical CHF

18 %

Everolimus

No relevant cardiotoxicity
  
Erlotinib

Venous thromboembolism

3.9–11 %
 
Ischemia

2.3 %

5-Fluorouracil

Ischemia or severe ventricular arrhythmias

1–68 %
 
Gemcitabine

No cardiotoxicity
  
Idarubicin

Heart failure

5–18 %
 
Ifosfamide

CHF

17 %

>12.5 g/m2

Imatinib

CHF

0.5–1.7 %

300 mg/d

Il-2

Hypotension

Rare
 
Interferon alfa

Hypotension

Rare
 
Lapatinib

QT prolongation

16 %
 
CHF

1.5–2.2 %

Lenalidomide

Venous thromboembolism

1–58 %
 
Liposomal anthracyclines

Heart failure

2 %
 
Mitomycin C

Heart failure

3 %
 
Mitoxantrone

Heart failure

2.6 %

>150 mg/mq

Nilotinib

QT prolongation

1–10 %
 
Paclitaxel

Bradycardia

<1–31 %
 
Ischemia

<1–5 %

Pazopanib

Hypertension, heart failure
  
Pentostatin

Heart failure

Rare
 
Raltitrexed [5]

No cardiotoxicity, alone or in combination with irinotecan or oxaliplatin, good option in patients that experienced cardiotoxicity with 5-FUO or capecitabine
  
Retinoic acid

Heart failure, pericardial effusion, hypotension

Rare
 
Rituximab

Hypotension, angioedema
  
Sorafenib

Ischemia

2.7–3 %
 
Hypertension

17–43 %

Sunitinib

Hypertension

5–47 %
 
Systolic and diastolic dysfunction, heart failure

1.7–3 %

Tamoxifen

Thromboembolic complications
  
Tivozanib

No data
  
Trastuzumab [1]

CHF and LVD

2–28 %
 
Vandetanib

QTc prolongation

<3 %
 
Vinca alkaloids

Myocardial ischemia
  
Vorinostat

QT prolongation

3.5–6 %
 
Venous thromboembolism

4.7–8 %


1. Yeh ETH. Cardiovascular complications of Cancer Therapy. JACC. 2009;53:2231

2. Ozkan HA. Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high-dose etoposide stem cell mobilization regimens with N-terminal pro-B-type natriuretic peptide. Transfus Apher Sci. 2014;50(1):46

3. Kupari M. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmia, heart failure and autopsy findings. Bone Marrow Transplant. 1990;5:91

4. Lotrionte M. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112

5. Ransom D. Final results of ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Ann Oncol. 2014;1:11




Table 7.2
What cancer/what possible drug/what possible complication: breast

























Cancer type
Possible drug
Possible complication
 
5-Fluorouracil, epirubicin, cyclophosphamide followed by trastuzumab [1]
Heart failure, ischemia

Docetaxel + cyclophosphamide + methotrexate + 5-FO [2, 3]
Ischemia, heart failure

Paclitaxel, [4] trastuzumab, [5, 6] bevacizumab, gemcitabine, lapatinib, capecitabine, mitoxantrone, etoposide; letrozole, fadrozole, vorozole, formestane, exemestane, anastrozole [7]
Thromboembolic complications, ischemia, heart failure, hypertension, bradycardia

Tamoxifen [8]
Thromboembolic complications


1. Peto R. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomized trials. Lancet. 2012;379:432

2. Jones SE. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381

3. Jones S. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research trial 9735. J Clin Oncol. 2009;27:1177

4. Sparano JA. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663

5. Perez EA. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366

6. Piccart M. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. First result of HERA trial. N Engl J Med. 2005;353:1659

7. Carrick S. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009, Issue http://​www2.​cochrane.​org/​reviews/​en/​subtopics/​52.​html)

8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687



Table 7.3
What cancer/what possible drug/what possible complication: bladder
























Cancer type
Possible drug
Possible complication
 
Cisplatin, methotrexate, vinblastine [1, 2]
Heart failure, ischemia
 
Paclitaxel, cisplatin, gemcitabine [3]
Heart failure, ischemia, bradycardia, thromboembolic complications
 
Doxorubicin, epirubicin, paclitaxel, docetaxel, oxaliplatin, topotecan, lapatinib, gefitinib, bortezomib, vinflunine
Heart failure, ischemia, bradycardia, thromboembolic complications, prolong QT


1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202

2. Griffiths G, International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Can Clinical Studies Group); European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171

3. Paz-Ares L, on behalf of the SOGUG and GUO-AEU groups. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the SOGUG (Spanish Oncology Genito-Urinary Group) 99/01 study. ASCO. 2010;(abst)



Table 7.4
What cancer/what possible drug/what possible complication: gastrointestinal











Cancer type
Possible drug
Possible complication
< div class='tao-gold-member'>

Only gold members can continue reading. Log In or Register to continue

Related posts:

  1. Introduction
  2. Evaluation of the Oncologic Patient Before, During, and After Chemotherapy
  3. Physiopathology and Toxic Heart Effects of Chemotherapy Drugs
  4. Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications

Stay updated, free articles. Join our Telegram channel
Tags:
Jul 10, 2016 | Posted by in CARDIOLOGY | Comments Off on Synthetic Tables

Full access? Get Clinical Tree

 Get Clinical Tree app for offline access